Apollo Hospitals Enterprise Limited

Sector: Healthcare, Hospital Chains  |  HQ: Chennai, Tamil Nadu  |  Founded: 1979  |  Employees: ~70,000

Listed as: NSE / BSE listed; Nifty 50 constituent; India's largest hospital chain  |  NSE / BSE  |  Ticker: APOLLOHOSP.NS  |  Website →

Key people

• Prathap C. Reddy (Founder Chairman)
• Suneeta Reddy (Managing Director)

Company overview

Apollo Hospitals Enterprise Limited is India's largest integrated healthcare company, with 73 hospitals, 5,000+ pharmacies, 800+ clinics, 2,500+ diagnostic centres, and a growing digital health platform. Founded in 1979 by Dr Prathap C. Reddy in Chennai, the Apollo Group is the country's most-recognised hospital brand and operates across the full continuum of care from primary clinics to tertiary and quaternary hospitals. FY25 consolidated revenue was approximately ₹20,500 crore with PAT of ₹1,250 crore. Apollo Hospitals is a Nifty 50 constituent and one of the most actively traded healthcare stocks on Indian markets.

Business model

Apollo operates five reporting segments. Healthcare Services (the hospital chain) is the largest by revenue and EBITDA. Apollo Health and Lifestyle (AHLL) covers primary care, clinics, day-surgery, fertility (Apollo Fertility), and chronic disease management. Apollo HealthCo Limited operates the integrated pharmacy distribution (5,000+ Apollo Pharmacy outlets across India, the largest pharmacy chain) and the digital health platform (Apollo 24|7). Diagnostic services through Apollo Diagnostics and Apollo Medical Centres provide outpatient testing. International operations cover Dhaka (Bangladesh), Kuala Lumpur (Malaysia), and Muscat (Oman).

Operating segments

Recent developments

November 2025 – May 2026

Apollo Hospitals demonstrated robust financial performance in FY26, with Q2 profit growth of 26% year-over-year [10], building on a strong full-year showing [1]. The company's credit profile was reinforced when CRISIL reaffirmed its AA+ rating and revised the outlook to positive [7], signaling improved financial resilience. An interim dividend of ₹10 per share was also declared during the period [3]. In corporate structuring, the long-anticipated demerger of the pharmacy and healthtech businesses moved closer to completion after NSE cleared the proposed separation of multiple health businesses [9], with shares rising approximately 2% on the news [4]. Strategically, Apollo strengthened its oncology vertical by appointing Dr Harit Kumar Chaturvedi as CEO of the Oncology Network [5], a move reflecting the company's focus on expanding high-margin specialty services amid growing cancer care demand in India. Analyst coverage suggests the combination of strong growth and expansion plans could drive meaningful upside [8].

Sources (6)

1. Apollo Hospitals Enterprise Limited Strong FY26 Performance and Strategic Healthcare Expansion - InvestyWise · InvestyWise · Wed, 20 May 2026
2. Apollo Hospitals Enterprise Gets CRISIL AA+ Rating Reaffirmation with Positive Outlook Revision - scanx.trade · scanx.trade · Tue, 27 Jan 2026
3. Apollo Hospitals shares rise 2% after NSE clears demerger of multiple health businesses - Fortune India · Fortune India · Wed, 24 Dec 2025
4. Apollo Hospitals' Pharmacy, Healthtech Businesses Inch Closer to Demerger - Medical Dialogues · Medical Dialogues · Thu, 25 Dec 2025
5. Apollo Hospitals appoints Dr Harit Kumar Chaturvedi CEO of Oncology Network - ET HealthWorld · ET HealthWorld · Mon, 20 Apr 2026
6. Apollo Hospitals Enterprise Reports 26% Profit Increase in Q2 FY26 - India News Network · India News Network · Sat, 08 Nov 2025

Financial performance and recent trajectory

Apollo Hospitals reported FY25 consolidated revenue of approximately ₹20,500 crore with EBITDA of ₹3,200 crore. EBITDA margin scaled to approximately 16 percent in FY25 from 13 percent in FY23 as bed-occupancy levels recovered post-pandemic and as the Apollo HealthCo digital business scaled. Capital expenditure run-rate is ₹1,000 to ₹1,500 crore per year with bed additions at Mumbai, Pune, and Bangalore the principal investment areas.

Stock performance and shareholder context

Apollo Hospitals (NSE: APOLLOHOSP, BSE: 508869) is a Nifty 50 constituent. The Reddy family holds approximately 30 percent. The stock has delivered strong returns over the FY23-FY25 window as occupancy and pricing recovered post-pandemic and as Apollo HealthCo monetised the digital and pharmacy platform.

12-month price trajectory

Monthly closes over the last 12 months. Source: Yahoo Finance.

Competitive position

In Indian hospital chains, principal competitors include Fortis Healthcare, Max Healthcare, Manipal Hospitals, Narayana Health, Aster DM Healthcare, and Medanta. Apollo's brand strength, the breadth of services across primary to tertiary care, and the Apollo Pharmacy distribution moat are the structural advantages. In organised pharmacy retail, principal competitors are MedPlus Health Services, Tata 1mg, and PharmEasy.

Key risks

Doctor talent retention and compensation inflation; pricing regulation (NPPA orders on cardiac stents, knee implants, oncology); medical insurance penetration trajectory; private equity-funded competitor expansion (Manipal, Aster); digital and tele-medicine disruption; hospital construction project execution risk.

Outlook

Strong outlook on the secular growth of Indian healthcare with rising insurance penetration, ageing demographics, and lifestyle disease burden. Apollo is the benchmark for any new entrant in multi-specialty hospitals, organised pharmacy retail, or integrated digital health. The Apollo HealthCo monetisation roadmap is the principal investor catalyst over FY26-FY28.

KAMRIT point of view

Building or competing with Apollo?

KAMRIT advises promoters, family offices, and global enterprises evaluating greenfield entry into the healthcare sector. Our Bankable DPR with Cost Model and ROI benchmarks your project economics against the listed-company cost structure of Apollo and peers. The Execution Partnership tier covers everything from incorporation through commissioning. A 20-minute scoping call with our partners is free.

View all 3 related project reports → Book a scoping call

Related KAMRIT project reports

These reports use Apollo Hospitals Enterprise Limited in benchmarking and competitive analysis sections.

Disclaimer: This profile is compiled by KAMRIT Financial Services LLP for educational and benchmarking purposes only. It is not investment advice, a recommendation to buy or sell securities, or a solicitation. Stock data is provided by Yahoo Finance and may be delayed by up to 20 minutes. Company financial commentary draws on publicly available filings, exchange disclosures, and KAMRIT industry research. Readers should consult a SEBI-registered investment adviser before making investment decisions. KAMRIT is a financial services and compliance firm, not a SEBI-registered investment adviser.